AR mRNA stability is increased with AR-antagonist resistance via 3′UTR variants
Advanced prostate cancer is often treated with AR antagonists w hich target the androgen receptor (AR) on which the growth of the tumour depends. Prosta te cancer often develops AR-antagonist resistance via a plethora of mechanisms, many of which are as yet unknown, but it is thought that AR upregul...
Main Authors: | D A Dart, K Ashelford, W G Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2019-12-01
|
Series: | Endocrine Connections |
Subjects: | |
Online Access: | https://doi.org/10.1530/EC-19-0340 |
Similar Items
-
SWATH-MS Based Proteomic Profiling of Prostate Cancer Cells Reveals Adaptive Molecular Mechanisms in Response to Anti-Androgen Therapy
by: Chamikara Liyanage, et al.
Published: (2021-02-01) -
Intracranial Assessment of Androgen Receptor Antagonists in Mice Bearing Human Glioblastoma Implants
by: Nomi Zalcman, et al.
Published: (2023-12-01) -
Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
by: Ga Yeong Kim, et al.
Published: (2021-04-01) -
Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer
by: Avinash Khadela, et al.
Published: (2022-12-01) -
DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER
by: S. V. MISHUGIN, et al.
Published: (2016-12-01)